

Acute Renal Failure (ARF) (Acute Kidney Injury) Treatment Pipeline Review H2 2016

Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, August 30, 2016
/EINPresswire.com/ -- Summary

[‘Acute Renal Failure \(ARF\) \(Acute Kidney Injury\) - Pipeline Review, H2 2016’](#), provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and

discontinued projects.

Complete report details @ <https://www.wiseguyreports.com/reports/619296-acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619296-acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h2-2016>



Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619296-acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10

Therapeutics Development 11

Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11

Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by

Universities/Institutes	15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products	16
Late Stage Products	16
Clinical Stage Products	17
Early Stage Products	18
Unknown Stage Products	19
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies	20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes	22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development	23
A1M Pharma AB	23
Adrenomed AG	24
Am-Pharma B.V.	25
Angion Biomedica Corp.	26
Atox Bio Ltd.	27
Cellmid Limited	28
Complexa, Inc.	29
DiaMedica Inc.	30
Digna Biotech, S.L.	31
DURECT Corporation	32
F. Hoffmann-La Roche Ltd.	33
G1 Therapeutics, Inc.	34
Kringle Pharma, Inc.	35
NephroGenex, Inc.	36
NeuroVive Pharmaceutical AB	37
Noorik Biopharmaceuticals AG	38
Noxxon Pharma AG	39
Orion Oyj	40
ProMetic Life Sciences Inc.	41
Quark Pharmaceuticals, Inc.	42
SBI Pharmaceuticals Co., Ltd.	43
Spherium Biomed S.L.	44
STATegics, Inc.	45
Stealth BioTherapeutics Inc.	46
Thrasos Therapeutics Inc.	47
Torrent Pharmaceuticals Limited	48
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment	49
Assessment by Monotherapy Products	49
Assessment by Combination Products	50
Assessment by Target	51
Assessment by Mechanism of Action	53
Assessment by Route of Administration	55
Assessment by Molecule Type	57
Drug Profiles	59
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile	59
Product Description	59
Mechanism Of Action	59
R&D Progress	59
A1M-001 - Drug Profile	60
Product Description	60
Mechanism Of Action	60

R&D Progress 60
AB-103 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
adrecizumab - Drug Profile 64
Product Description 64
Mechanism Of Action 64

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619296

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.